ACTRN12609000725268进行中（未招募）未知
A Prospective, Multicentre Trial to Assess the safety and effectiveness of an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Lesion in a Small Vessel (2.25 - 2.5mm diameter)
Boston Scientific Pty Ltd0 个研究点目标入组 94 人开始时间: 2009年8月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Patient is eligible for percutaneous coronary intervention (PCI)
- •2. Patient has documented stable angina
- •pectoris, or documented silent ischaemia, or
- •unstable angina pectoris
- •3. Patient is acceptable candidate for Coronary Artery Bypass Graft (CABG)
- •4. Patient has left ventricular ejection fraction of >30%
- •5. Target lesion must be de novo and located within native coronary artery with diameter 2.25mm to 2.50mm
- •6. Target lesion must be <28mm in length
- •7. Target lesion must be in a major coronary artery or branch with visually estimated stenosis >50% and <100%
排除标准
- •1. Clinical symptoms or Electrocardiogram (ECG) changes consistent with Myocardial Infarction (MI)
- •2. Patient has known diagnosis of recent MI
- •(within 72 hours prior to index procedure) and has elevated enzymes at time of index procedure
- •3. Target vessel or side branch treated with any type of PCI within 12 months prior to index procedure
- •4. Patient is receiving chronic anticoagulation therapy for indications other than acute coronary syndrome
- •5. Females who are pregnant, nursing/lactating or planning to procreate within 12 months of the index procedure
研究者
相似试验
招募中
不适用
Evaluation of the Safety & Effectiveness of the PROMUS Element Everolimus-Eluting Coronary Stent System in patients with new or untreated atherosclerotic coronary artery lesionsACTRN12609000724279Boston Scientific Pty Ltd102
招募中
3 期
A study to estimate the Safety and acceptability of Lumateperone as another treatment used together with the primary treatment in the Treatment of Patients with Major Depressive DisorderCTRI/2023/04/052094Intra-Cellular Therapies, Inc.
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001172-41-BGIntra-Cellular Therapies, Inc.760
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMedDRA version: 20.0Level: LLTClassification code 10025458Term: Major depressive disorder, recurrent episode, moderate degreeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10081270Term: Major depressive disorderSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2021-001172-41-FIIntra-Cellular Therapies, Inc.760
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001172-41-SKIntra-Cellular Therapies, Inc.760